Recombinant Human KIR2DL2(His22 - His245) fused with Fc region of Human IgG1 at C-terminal was expressed in NS0.
Predicted N Terminal:
Lyophilized from a 0.2 μm filtered solution in PBS.
Measured by its ability to bind HEK293T human embryonic kidney cells in a flow cytometry assay. When 1 μg of Recombinant Human KIR2DL2/CD158b1 Fc Chimera is added to 5 x 10^5 HEK293T cells, >20% of the cells will bind to the protein.
Predicted Molecular Mass: 51.2 (monomer) kDa;SDS-PAGE: 65-75 kDa, reducing conditions.
<1.0 EU per 1 μg of the protein by the LAL method.
>90%, by SDS-PAGE under reducing conditions and visualized by silver stain
Avoid repeated freeze-thaw cycles.12 months from date of receipt, -20 to -70 centigrade as supplied.1 month, 2 to 8 centigrade under sterile conditions after reconstitution.3 months, -20 to -70 centigrade under sterile conditions after reconstitution.
Reconstitute at 100 μg/mL in PBS.